Compass Therapeutics (CMPX) Short Interest Ratio & Short Volume $2.78 +0.16 (+5.92%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$2.78 0.00 (0.00%) As of 07/3/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Compass Therapeutics Short Interest DataCompass Therapeutics (CMPX) has a short interest of 7.39 million shares, representing 8.40% of the float (the number of shares available for trading by the public). This marks a -0.54% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.2, indicating that it would take 5.2 days of the average trading volume of 971,729 shares to cover all short positions.Current Short Interest7,390,000 sharesPrevious Short Interest7,430,000 sharesChange Vs. Previous Month-0.54%Dollar Volume Sold Short$17.81 millionShort Interest Ratio5.2 Days to CoverLast Record DateJune 15, 2025Outstanding Shares138,280,000 sharesFloat Size87,950,000 sharesShort Percent of Float8.40%Today's Trading Volume794,726 sharesAverage Trading Volume971,729 sharesToday's Volume Vs. Average82% Short Selling Compass Therapeutics? Sign up to receive the latest short interest report for Compass Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCMPX Short Interest Over TimeCMPX Days to Cover Over TimeCMPX Percentage of Float Shorted Over Time Compass Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/20257,390,000 shares $17.81 million -0.5%8.4%5.2 $2.41 5/31/20257,430,000 shares $15.90 million +7.5%8.5%5.2 $2.14 5/15/20256,910,000 shares $13.96 million -9.4%7.9%4.9 $2.02 4/30/20257,630,000 shares $14.19 million -6.6%8.7%5.2 $1.86 4/15/20258,170,000 shares $13.89 million +23.4%9.3%5.1 $1.70 3/31/20256,620,000 shares $12.58 million +43.6%8.2%3.1 $1.90 3/15/20254,610,000 shares $11.34 million +24.6%5.7%3.2 $2.46 2/28/20253,700,000 shares $10.73 million +4.8%4.6%2.7 $2.90 2/15/20253,530,000 shares $11.93 million +28.4%4.4%2.7 $3.38 1/31/20252,750,000 shares $8.86 million -13.8%3.3%2.1 $3.22 Get the Latest News and Ratings for CMPX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20253,190,000 shares $7.88 million +44.3%3.8%2.9 $2.47 12/31/20242,210,000 shares $3.20 million +5.2%2.6%2.5 $1.45 12/15/20242,100,000 shares $3.07 million +44.8%2.5%4.4 $1.46 11/30/20241,450,000 shares $2.36 million +17.9%1.7%3 $1.63 11/15/20241,230,000 shares $1.70 million -31.3%1.4%2.5 $1.38 10/31/20241,790,000 shares $2.94 million -19.0%2.1%3.9 $1.64 10/15/20242,210,000 shares $4.22 million -11.2%2.6%4.7 $1.91 9/30/20242,490,000 shares $4.58 million +8.3%2.9%5.9 $1.84 9/15/20242,300,000 shares $3.80 million +23.7%2.7%5.3 $1.65 8/31/20241,860,000 shares $2.94 million +4.5%2.2%4.2 $1.58 8/15/20241,780,000 shares $2.06 million -5.8%2.1%4.5 $1.16 7/31/20241,890,000 shares $1.95 million -6.4%2.1%5 $1.03 7/15/20242,020,000 shares $2.04 million +11.0%2.3%6.2 $1.01 6/30/20241,820,000 shares $1.82 million +15.2%2.1%5.1 $1.00 6/15/20241,580,000 shares $1.75 million +1.9%1.8%5.2 $1.11 5/31/20241,550,000 shares $2.19 million -5.5%1.8%5 $1.41 5/15/20241,640,000 shares $2.53 million No Change1.9%4.8 $1.54 4/30/20241,640,000 shares $2.36 million +1.2%1.9%4.6 $1.44 4/15/20241,620,000 shares $2.56 million No Change1.9%4.4 $1.58 3/31/20241,620,000 shares $3.21 million -13.8%2.0%3.3 $1.98 3/15/20241,880,000 shares $4.31 million +2.2%2.3%3.6 $2.29 2/29/20241,840,000 shares $3.28 million -6.6%2.4%3.5 $1.78 2/15/20241,970,000 shares $3.47 million -9.6%2.6%3.6 $1.76 1/31/20242,180,000 shares $2.83 million +10.1%2.8%4.1 $1.30 1/15/20241,980,000 shares $3.58 million -12.8%2.6%3.9 $1.81 12/31/20232,270,000 shares $3.54 million +8.1%2.8%4.4 $1.56 12/15/20232,100,000 shares $3.34 million -21.4%2.6%5.9 $1.59 11/30/20232,670,000 shares $4.41 million -10.1%3.3%8.5 $1.65 11/15/20232,970,000 shares $4.40 million +4.2%3.6%10.8 $1.48 10/31/20232,850,000 shares $5.13 million -12.8%3.5%13 $1.80Gold buying hits 4-year high (Ad)The perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an epic bull rally in gold. JP Morgan and Goldman Sachs have a price target of $4,000. My research tells me gold could surpass $5,000 in the coming months. Folks using a very specific gold strategy since the 80s could have made more than 60 TIMES their money. Today, you can take advantage of a similar setup for around $10Gold prediction: $5,000/oz. or higher is coming 10/15/20233,270,000 shares $6.25 million -23.2%4.0%13.5 $1.91 9/30/20234,260,000 shares $8.39 million -5.1%5.2%16.5 $1.97 9/15/20234,490,000 shares $9.56 million +1.4%5.5%14.6 $2.13 8/31/20234,430,000 shares $10.32 million -1.1%5.5%8.4 $2.33 8/15/20234,480,000 shares $11.07 million -2.4%5.5%8.1 $2.47 7/31/20234,590,000 shares $13.17 million -1.3%6.0%8 $2.87 7/15/20234,650,000 shares $13.35 million +8.4%6.1%8.1 $2.87 6/30/20234,290,000 shares $13.64 million +93.2%5.9%7.4 $3.18 6/15/20232,220,000 shares $7.28 million +8.8%3.3%3.9 $3.28 5/31/20232,040,000 shares $5.92 million -1.0%3.0%5.9 $2.90 5/15/20232,060,000 shares $6.84 million -5.9%3.1%5.9 $3.32 4/30/20232,190,000 shares $6.59 million +5.3%3.3%6 $3.01 4/15/20232,080,000 shares $6.45 million +4.5%3.1%4.8 $3.10 3/31/20231,990,000 shares $6.51 million -6.6%3.0%4.7 $3.27 3/15/20232,130,000 shares $7.58 million +17.7%3.2%5.7 $3.56 2/28/20231,810,000 shares $6.86 million -18.1%2.7%4.9 $3.79 2/15/20232,210,000 shares $8.80 million +16.3%3.2%6.5 $3.98 1/31/20231,900,000 shares $7.60 million +84.5%2.5%6.2 $4.00 1/15/20231,030,000 shares $5.35 million +10.2%1.4%4.5 $5.19 12/30/2022935,000 shares $4.70 million +197.3%1.2%5.4 $5.03 12/15/2022314,500 shares $1.41 million +112.6%0.4%1.8 $4.49 11/30/2022147,900 shares $607.87 thousand +36.2%0.2%0.8 $4.11 11/15/2022108,600 shares $515.85 thousand -17.1%0.2%0.6 $4.75 10/31/2022131,000 shares $413.96 thousand -21.9%0.2%0.7 $3.16 10/15/2022167,800 shares $523.54 thousand -13.2%0.3%1 $3.12 9/30/2022193,400 shares $440.95 thousand +271.2%0.4%1.1 $2.28 9/15/202252,100 shares $162.55 thousand +143.5%0.1%0.3 $3.12 8/31/202221,400 shares $58.85 thousand -41.4%0.0%0.2 $2.75 8/15/202236,500 shares $105.85 thousand -22.3%0.1%0.3 $2.90 7/31/202247,000 shares $122.20 thousand -36.1%0.1%0.3 $2.60 7/15/202273,500 shares $205.80 thousand -30.5%0.1%0.3 $2.80 6/30/2022105,800 shares $280.37 thousand +25.7%0.2%0.5 $2.65 6/15/202284,200 shares $196.19 thousand -46.4%0.2%0.4 $2.33 5/31/2022157,100 shares $479.16 thousand -32.1%0.3%0.8 $3.05 5/15/2022231,400 shares $587.76 thousand +82.2%0.4%1.1 $2.54 CMPX Short Interest - Frequently Asked Questions What is Compass Therapeutics' current short interest? Short interest is the volume of Compass Therapeutics shares that have been sold short but have not yet been covered or closed out. As of June 15th, traders have sold 7,390,000 shares of CMPX short. 8.40% of Compass Therapeutics' shares are currently sold short. Learn More on Compass Therapeutics' current short interest. What is a good short interest ratio for Compass Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CMPX shares currently have a short interest ratio of 5.0. Learn More on Compass Therapeutics's short interest ratio. Which institutional investors are shorting Compass Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Compass Therapeutics: Nomura Holdings Inc., HAP Trading LLC, and Affinity Asset Advisors LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Compass Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.40% of Compass Therapeutics' floating shares are currently sold short. Is Compass Therapeutics' short interest increasing or decreasing? Compass Therapeutics saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 7,390,000 shares, a decrease of 0.5% from the previous total of 7,430,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Compass Therapeutics' float size? Compass Therapeutics currently has issued a total of 138,280,000 shares. Some of Compass Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Compass Therapeutics currently has a public float of 87,950,000 shares. How does Compass Therapeutics' short interest compare to its competitors? 8.40% of Compass Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Compass Therapeutics: 89BIO (9.84%), ANI Pharmaceuticals, Inc. (10.44%), Mesoblast Limited (2.59%), Edgewise Therapeutics, Inc. (16.25%), Janux Therapeutics, Inc. (21.42%), Travere Therapeutics, Inc. (12.14%), CureVac N.V. (2.72%), Structure Therapeutics Inc. Sponsored ADR (15.12%), Aurinia Pharmaceuticals Inc (8.82%), Amphastar Pharmaceuticals, Inc. (11.80%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Compass Therapeutics stock? Short selling CMPX is an investing strategy that aims to generate trading profit from Compass Therapeutics as its price is falling. CMPX shares are trading up $0.16 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Compass Therapeutics? A short squeeze for Compass Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CMPX, which in turn drives the price of the stock up even further. How often is Compass Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CMPX, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies 89BIO Short Interest ANI Pharmaceuticals Short Interest Mesoblast Short Interest Edgewise Therapeutics Short Interest Janux Therapeutics Short Interest Travere Therapeutics Short Interest CureVac Short Interest Structure Therapeutics Short Interest Aurinia Pharmaceuticals Short Interest Amphastar Pharmaceuticals Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CMPX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.The robotics revolution is here. And it's set to impact everything from how we manufacture goods to how we ...Weiss Ratings | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMPX Stock Alerts